Awen Oncology
Awen Oncology aims to transform cancer treatment by delivering first-in-class therapeutics targeting novel, undrugged cancer-specific factors. Their mission is to discover and develop innovative oncology treatments that address the complexities of cancer, with a focus on creating therapies with fewer side effects and improved efficacy. They combine high-throughput biology with advanced computational techniques to identify new therapeutic targets and develop effective treatments rapidly. The company collaborates with strategic partners, including the University of Cambridge Milner Therapeutic Institute, and is committed to revolutionizing cancer treatment to offer new hope for patients worldwide.
Industries
Nr. of Employees
small (1-50)
Products
Target Therapies
Development of therapeutics targeting cancer-specific oncogenic factors to improve patient outcomes and reduce side effects.
Target Therapies
Development of therapeutics targeting cancer-specific oncogenic factors to improve patient outcomes and reduce side effects.
Innovative Oncology Drug Discovery
Discovery and development of oncology treatments targeting proteins unique to cancer cells, aiming for improved efficacy and fewer side effects.
Innovative Oncology Drug Discovery
Discovery and development of oncology treatments targeting proteins unique to cancer cells, aiming for improved efficacy and fewer side effects.
Target Therapies
Development of therapeutics targeting cancer-specific oncogenic factors to improve patient outcomes and reduce side effects.
Target Therapies
Development of therapeutics targeting cancer-specific oncogenic factors to improve patient outcomes and reduce side effects.
Innovative Oncology Drug Discovery
Discovery and development of oncology treatments targeting proteins unique to cancer cells, aiming for improved efficacy and fewer side effects.
Innovative Oncology Drug Discovery
Discovery and development of oncology treatments targeting proteins unique to cancer cells, aiming for improved efficacy and fewer side effects.
Services
Partner-focused collaboration to advance oncology target discovery and early-stage therapeutic programs in partnership with academic, industry, and patient-advocacy stakeholders.
Execution and coordination of preclinical research activities to advance candidates through lead optimization and towards regulatory engagement.
Partner-focused collaboration to advance oncology target discovery and early-stage therapeutic programs in partnership with academic, industry, and patient-advocacy stakeholders.
Execution and coordination of preclinical research activities to advance candidates through lead optimization and towards regulatory engagement.
Expertise Areas
- Oncology drug discovery
- Cancer target identification and validation
- Preclinical development and IND-enabling activities
- High-throughput cellular and molecular assays
Key Technologies
- High-throughput cell-based assays
- Molecular biology techniques
- Computational biology / advanced computational analysis
- Small-molecule medicinal chemistry
News & Updates
This award supports small molecule start-ups by providing essential chemistry resources and expertise to accelerate drug discovery.
Recognition for innovative contributions in the field of oncology.
Selected as one of the UK’s top six new oncology ventures.
Recognition as a promising new company in the biotech sector.
Partnership to support high growth initiatives.
Development of therapeutic pipelines.
This award supports small molecule start-ups by providing essential chemistry resources and expertise to accelerate drug discovery.
Recognition for innovative contributions in the field of oncology.
Selected as one of the UK’s top six new oncology ventures.
Recognition as a promising new company in the biotech sector.
Partnership to support high growth initiatives.
Development of therapeutic pipelines.